From ancient immunity to disruptive cure
We harness the immense diversity of microbial antiphage defense into revolutionary technologies and therapeutics
Founded in 2017 and based in Israel, Pantheon Biosciences is an early-stage biotechnology company committed to harnessing the immense diversity of bacterial immunity into revolutionary biomedical platforms and therapeutics. We are leveraging unexploited insights hidden in bacterial defense systems to develop innovative antiviral drugs and next-generation therapeutics for molecular engineering. Driven by cutting-edge research from Prof. Rotem Sorek of The Weizmann Institute of Science, we develop Pantheon’s proprietary novel antiviral small molecules, creating a broad product portfolio derived from the novel bacterial defense systems.
The Sorek lab at Weizmann Institute of Science has developed revolutionary technology for systematic discovery of new immune systems. This technology involves massive computational predictions followed by experimental validation.
The natural nucleoside analogs in development by Pantheon, intend to bring innovation to a validated class of antiviral therapeutics and to address acute unmet needs. Pantheon is deciphering multiple bacterial defense systems aiming to uncover novel biological machineries and to develop disruptive technologies and products.